Clinical Trials Logo
  1. Home
  2. Leptomeningeal Metastasis
  3. NCT04356118

Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Leptomeningeal Metastasis Clinical Trial

Official title:
Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Clinical Trial Summary

The purpose of this study is to observe the clinical effect and safety of Recombinant Human Endostatin in non-small cell lung cancer with leptomeningeal metastasis

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04356118
Study type Interventional
Source Hebei Medical University
Contact Hui Bu
Phone 86-13831106903
Email buhuimy1@163.com
Status Not yet recruiting
Phase Phase 4
Start date June 2020
Completion date June 2023
View Details
See also
  Status Clinical Trial Phase
Terminated NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT04178343 - Tomotherapy for Leptomeningeal Metastases N/A
Recruiting NCT06399926 - Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
Not yet recruiting NCT06441045 - Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI Phase 2
Recruiting NCT04425681 - Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05598853 - Intrathecal Double Checkpoint Inhibition Phase 1
Recruiting NCT02803619 - A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis N/A
Recruiting NCT05746754 - Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis N/A
Not yet recruiting NCT04148898 - Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis Phase 2
Completed NCT04420598 - DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease Phase 2
Completed NCT02071056 - Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
Recruiting NCT05385185 - Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer Phase 2
Terminated NCT04729348 - Pembrolizumab And Lenvatinib In Leptomeningeal Metastases Phase 2
Recruiting NCT06304441 - Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer N/A
Not yet recruiting NCT06296745 - Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. Phase 2
Recruiting NCT04778800 - A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) N/A
Not yet recruiting NCT06282874 - Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases Phase 4
Not yet recruiting NCT04356222 - Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis Phase 4
Not yet recruiting NCT06462222 - Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors Phase 1/Phase 2